Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Apple stock rises after falling Thursday by the most since August, Alphabet stock is up after the Supreme Court upholds a ban ...
Luxury bellwether regains crown as drugmaker slips on concerns it will have to cut weight loss medication prices in US ...
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...
Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback